蛋白酶体抑制剂Bortezomib及其在多发性骨髓瘤中的研究进展

Proteasome inhibitor bortezomib and its development in multiple myeloma

蛋白酶体抑制剂Bortezomib通过抑制蛋白酶体及NF-k B使骨髓瘤细胞凋亡,从Borte- zomib作用分子机制、药理作用、临床前研究、临床疗效评价、耐药及联合用药等方面进行了阐述。

Proteasome inhibitor PS-341,a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells,induces apoptosis in multiple myeloma(MM)cells.This review briefly discussed about molecular mechanisms,the pharmacological action,clinical evaluation and clinical evaluation, drug resistance of bortezomib.